AlphaCrest Capital Management’s Allogene Therapeutics ALLO Stock Holding History

AlphaCrest Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-55,454	Closed	-$599K	–	54
2022 Q3	$599K	Buy	55,454 +34,176	+161%	+$464K	0.04%	898
2022 Q2	$243K	Sell	21,278 -28,296	-57%	-$251K	0.01%	1168
2022 Q1	$452K	Buy	49,574 +22,540	+83%	+$235K	0.03%	942
2021 Q4	$403K	Buy	+27,034	New	+$477K	0.02%	1170
2021 Q3	–	Sell	-81,305	Closed	-$2.12M	–	1230
2021 Q2	$2.12M	Buy	81,305 +65,005	+399%	+$1.85M	0.09%	343
2021 Q1	$575K	Buy	16,300 +4,900	+43%	+$165K	0.03%	740
2020 Q4	$288K	Buy	+11,400	New	+$372K	0.02%	933

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AlphaCrest Capital Management's ALLO Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Allogene Therapeutics (ALLO) in Q4 2022, closing a stake of 55,454 shares — an estimated $599K sold.

AlphaCrest Capital Management first reported a position in ALLO in Q4 2020 and held it in 7 quarters. The position peaked at $2.12M in Q2 2021. 168 funds tracked by Wall St. Rank hold ALLO as of Q4 2022.

AlphaCrest Capital Management reported no remaining Allogene Therapeutics position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 55,454 Allogene Therapeutics shares in Q4 2022, an estimated $599K.
AlphaCrest Capital Management first reported a position in Allogene Therapeutics in Q4 2020 and held it in 7 quarters.
AlphaCrest Capital Management's Allogene Therapeutics position peaked at $2.12M in Q2 2021.
168 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.